0A4P Stock Overview
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NVN Liquidation, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0008 |
| 52 Week High | €1.28 |
| 52 Week Low | €0.0001 |
| Beta | 1.65 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.93% |
| 33 Year Change | -99.99% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4P | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.5% | 2.2% |
| 1Y | -99.9% | 0.7% | 8.0% |
Return vs Industry: 0A4P underperformed the UK Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: 0A4P underperformed the UK Market which returned 1.9% over the past year.
Price Volatility
| 0A4P volatility | |
|---|---|
| 0A4P Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A4P's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A4P's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 90 | Scott Plesha | www.novan.com |
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.
NVN Liquidation, Inc. Fundamentals Summary
| 0A4P fundamental statistics | |
|---|---|
| Market cap | US$29.97 |
| Earnings (TTM) | -US$32.05m |
| Revenue (TTM) | US$24.92m |
0.0x
P/S Ratio0.0x
P/E RatioIs 0A4P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4P income statement (TTM) | |
|---|---|
| Revenue | US$24.92m |
| Cost of Revenue | US$24.45m |
| Gross Profit | US$473.00k |
| Other Expenses | US$32.52m |
| Earnings | -US$32.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 1.90% |
| Net Profit Margin | -128.61% |
| Debt/Equity Ratio | -1,164.1% |
How did 0A4P perform over the long term?
See historical performance and comparison